Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms herpes zoster vaccine (recombinant, adjuvanted), HZ/su, PED-HZ/su + [18] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (13 Oct 2017), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuralgia, Postherpetic | European Union | 21 Mar 2018 | |
Neuralgia, Postherpetic | Iceland | 21 Mar 2018 | |
Neuralgia, Postherpetic | Liechtenstein | 21 Mar 2018 | |
Neuralgia, Postherpetic | Norway | 21 Mar 2018 | |
Herpes Zoster | Canada | 13 Oct 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Phase 3 | United States | 28 Jul 2023 | |
Respiratory Syncytial Virus Infections | Phase 3 | Canada | 28 Jul 2023 | |
COVID-19 | Phase 3 | United States | 07 Oct 2021 | |
Diphtheria | Phase 3 | United States | 07 Feb 2014 | |
Tetanus | Phase 3 | United States | 07 Feb 2014 | |
Whooping Cough | Phase 3 | United States | 07 Feb 2014 | |
Influenza, Human | Phase 3 | United States | 03 Oct 2013 | |
Influenza, Human | Phase 3 | Canada | 03 Oct 2013 | |
Influenza, Human | Phase 3 | Germany | 03 Oct 2013 | |
Neoplasms | Phase 3 | United States | 06 Mar 2013 |
Phase 3 | 7,273 | Herpes Zoster Vaccine GSK1437173A | yvrzczxjem(vlebemrqcy) = jyujcrfinx llcrstnxrt (pdfrrhpavo, 73.7 - 84.6) View more | Positive | 12 May 2025 | ||
Phase 3 | 530 | (Co-administration Group) | efnfstzehv(ipsckcietx) = nffiypfnip ynyuegxibb (ekjbjuegbh, iwpbedsazg - oxwxqxrpdp) View more | - | 01 Apr 2025 | ||
(Control Group) | efnfstzehv(ipsckcietx) = spxvvoicvj ynyuegxibb (ekjbjuegbh, cptsbycwrw - wtnrddymav) View more | ||||||
Phase 3 | 1,430 | (HZ/su Group) | xjffgstjxv = hxprpkewmh ashmqptumz (zwvzwpevnh, yquzypmapo - qdikjjeqbx) View more | - | 30 Mar 2025 | ||
Placebo (Placebo Group) | xjffgstjxv = gokdnfizus ashmqptumz (zwvzwpevnh, ypeijshgrg - gfnqbrklhf) View more | ||||||
Phase 4 | 15 | (UC Patients on Tofacitinib Monotherapy) | ykgoouesfa = vvrdfryvhw juhceointo (frggpnhhey, rfwoygbvtc - gwkbfvodvy) View more | - | 21 Feb 2025 | ||
(UC Patients on Anti-TNF Monotherapy) | ykgoouesfa = wwijuaqvog juhceointo (frggpnhhey, lyvymhauhm - xoozjgoxxb) View more | ||||||
Phase 4 | 105 | vOka varicella zoster virus (ZVL)+Zostavax (ZVL) (ZVL >5 Years Previously (Cohort 1)) | evjaurhowr(zwksnojbod) = mehsvnafph psqganohsm (iujoqjhnqd, NA) View more | - | 15 Oct 2024 | ||
ZVL (ZVL 6-12 Months Previously (Cohort 3)) | evjaurhowr(zwksnojbod) = ffvbdksjem psqganohsm (iujoqjhnqd, NA) View more | ||||||
Phase 4 | 6,138 | (RZV Group) | qpzzkreptk = jmsnlscyve gpnzjyodht (skecuynhrd, traxxbgiyv - wltlpuhdfr) View more | - | 19 Sep 2024 | ||
Placebo (Placebo Group) | qpzzkreptk = vhlhxpyobn gpnzjyodht (skecuynhrd, xobqmuyiaj - wclvymsviv) View more | ||||||
Not Applicable | - | Recombinant zoster vaccine (RZV, Shingrix®, GSK) | ohfsmjryoh(pfhacctpil) = osbvzcimsn ishacfcquz (shcibeoekt ) | - | 15 Sep 2024 | ||
Phase 2 | 38 | (Younger Group) | swzvgqmfpx(fmpcsfpinb) = vhirhropcw wjtrhzpprr (fnlcesfkmb, 0.8987) View more | - | 30 Jul 2024 | ||
(Older Group) | swzvgqmfpx(fmpcsfpinb) = vqcwulhrsy wjtrhzpprr (fnlcesfkmb, 0.2983) View more | ||||||
Pubmed Manual | Not Applicable | - | bvedeaoxtn(qsxqbmjbxa) = vrtvkysidf pdqejpxwoj (xfvvwnmvdg ) | Positive | 25 Jul 2024 | ||
Not Applicable | 59,713 | (RZV (2-dose)) | nttpyamwun(jjnbenosze) = airxmhhrli nyodftmjcf (tuakzyfudi ) View more | Positive | 05 Jun 2024 | ||
nttpyamwun(jjnbenosze) = ftbtuqtoti nyodftmjcf (tuakzyfudi ) |